Angeliki Malliri

Angeliki Malliri

Prof

Accepting PhD Students

If you made any changes in Pure these will be visible here soon.

Personal profile

Overview

The main focus of my lab’s research is investigating whether signalling by the small GTPase RAC1 could be a good therapeutic target in lung cancer and specifically in KRAS-mutant lung adenocarcinoma (KRASm-LUAD) and small cell lung cancer (SCLC). KRASm-LUAD and SCLC are major causes of morbidity and mortality, reflecting significant unmet clinical needs. RAC1 is required for KRASm-LUAD development and controls migration and invasion, cardinal features of malignant progression. However, RAC1 performs essential physiological roles and can antagonise tumour progression dependent on context: while generally promoting migration and invasion, RAC1-signalling can also do the opposite. Selectively targeting RAC1’s cancer-promoting effects is therefore critical to harnessing its full therapeutic potential. Interestingly, our research has highlighted that guanine nucleotide exchange factors (GEFs) stimulate RAC1 activity but also coordinate downstream effectors providing selectivity in RAC1-signalling. We are, therefore, currently evaluating the contribution of RAC1-GEF-signalling to KRASm-LUAD development and progression, and whether inhibiting RAC1-GEF signalling can sensitise KRASm-LUADs to KRAS inhibitors that have recently entered the clinic. We are also evaluating the role of RAC1-GEF-signalling in the development, plasticity and metastasis of SCLC.

In another project of my lab, in close collaboration with my main clinical collaborator Dr Colin Lindsay, we are looking into differences in signalling emanating from two different KRAS G12 mutations. This follows on from exciting in vivo and in vitro data from our lab that oncopotency and signalling downstream from two different KRAS G12 mutations can be diverse. We are also investigating mechanisms of resistance to KRAS inhibitors that have recently entered the clinic using either cell models or patient samples from the Christie Hospital, a major UK cancer hospital based in Manchester.

Expertise related to UN Sustainable Development Goals

In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):

  • SDG 3 - Good Health and Well-being

Education/Academic qualification

Doctor of Philosophy, National Hellenic Research Foundation

19901994

Bachelor of Science, Panepistimio Patron - University of Patras

19851989

External positions

Member of the Molecular and Cellular Medicine Board, Medical Research Council (MRC)

Jun 2017May 2019

Scientific Advisory Committee, Worldwide Cancer Research

1 Oct 201231 Oct 2017

Editorial Board, Small GTPases - Taylor & Francis Online

Research Beacons, Institutes and Platforms

  • Manchester Cancer Research Centre

Fingerprint

Dive into the research topics where Angeliki Malliri is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
  • 1 Similar Profiles

Collaborations and top research areas from the last five years

Recent external collaboration on country/territory level. Dive into details by clicking on the dots or